

# Momentous sprint at the 2156 Olympics?

Women sprinters are closing the gap on men and may one day overtake them.

The 2004 Olympic women's 100-metre sprint champion, Yuliya Nesterenko, is assured of fame and fortune. But we show here that — if current trends continue — it is the winner of the event in the 2156 Olympics whose name will be etched in sporting history forever, because this may be the first occasion on which the race is won in a faster time than the men's event.


The Athens Olympic Games could be viewed as another giant experiment in human athletic achievement. Are women narrowing the gap with men, or falling further behind? Some argue that the gains made by women in running events between the 1930s and the 1980s are decreasing as the women's achievements plateau<sup>1</sup>. Others contend that there is no evidence that athletes, male or female, are reaching the limits of their potential<sup>1,2</sup>.

In a limited test, we plot the winning times of the men's and women's Olympic finals over the past 100 years (ref. 3; for data set, see supplementary information) against the competition date (Fig. 1). A range of curve-fitting procedures were tested (for methods, see supplementary information), but there was no evidence that the addition of extra parameters improved the model fit significantly from the simple linear relationships shown here. The remarkably strong linear trends that were first highlighted over ten years ago<sup>2</sup> persist for the Olympic 100-metre sprints. There is no indication that a plateau has been reached by either male or female athletes in the Olympic 100-metre sprint record.

Extrapolation of these trends to the 2008 Olympiad indicates that the women's 100-metre race could be won in a time of  $10.57 \pm 0.232$  seconds and the men's event in  $9.73 \pm 0.144$  seconds. Should these trends continue, the projections will intersect at the 2156 Olympics, when — for the first time ever — the winning women's 100-metre sprint time of 8.079 seconds will be lower than that of the men's winning time of 8.098 seconds (Fig. 1). The 95% confidence intervals, estimated through Markov chain Monte Carlo simulation<sup>4</sup> (see supplementary information), indicate that this could occur as early as the 2064 or as late as the 2788 Games.

This simple analysis overlooks numerous confounding influences, such as timing accuracy, environmental variations, national boycotts and the use of legal and illegal stimulants. But it is also defended by the limited amount of variance that remains unexplained by these linear relationships.

So will these trends continue and can women really close the gap on men? Those who contend that the gender gap is widening



**Figure 1** The winning Olympic 100-metre sprint times for men (blue points) and women (red points), with superimposed best-fit linear regression lines (solid black lines) and coefficients of determination. The regression lines are extrapolated (broken blue and red lines for men and women, respectively) and 95% confidence intervals (dotted black lines) based on the available points are superimposed. The projections intersect just before the 2156 Olympics, when the winning women's 100-metre sprint time of 8.079 s will be faster than the men's at 8.098 s.

say that drug use explains why women's times were improving faster than men's, particularly as that improvement slowed after the introduction of drug testing<sup>1</sup>. However, no evidence for this is found here. By contrast, those who maintain that there could be a continuing decrease in gender gap point out that only a minority of the world's female population has been given the opportunity to compete (O. Anderson, [www.pponline.co.uk/encyc/0151.htm](http://www.pponline.co.uk/encyc/0151.htm)).

Whether these trends will continue at the Beijing Olympics in 2008 remains to be seen. Sports, biological and medical sciences should enable athletes to continue to improve on Olympic and world records, by fair means or foul<sup>5</sup>. But only time will tell whether in the 66th Olympiad the fastest human on the planet will be female.

**Andrew J. Tatem\***, **Carlos A. Guerra\***, **Peter M. Atkinson†**, **Simon I. Hay\*‡**

\*TALA Research Group, Department of Zoology, University of Oxford, Oxford OX1 3PS, UK  
e-mail: [andy.tatem@zoology.oxford.ac.uk](mailto:andy.tatem@zoology.oxford.ac.uk)

†School of Geography, University of Southampton, Highfield, Southampton SO17 1BJ, UK

‡Public Health Group, KEMRI/Wellcome Trust Research Laboratories, PO Box 43640, 00100 GPO, Nairobi, Kenya

1. Holden, C. *Science* **305**, 639–640 (2004).
2. Whipp, B. J. & Ward, S. A. *Nature* **355**, 25 (1992).
3. Rendell, M. (ed.) *The Olympics: Athens to Athens 1896–2004* 338–340 (Weidenfeld and Nicolson, London, 2003).
4. Gilks, W. R., Thomas, A. & Spiegelhalter, D. J. *Statistician* **43**, 169–178 (1994).
5. Vogel, G. *Science* **305**, 632–635 (2004).

Supplementary information accompanies this communication on Nature's website.

Competing financial interests: declared none.

## Lung cancer

### Intragenic ERBB2 kinase mutations in tumours

The protein-kinase family is the most frequently mutated gene family found in human cancer and faulty kinase enzymes are being investigated as promising targets for the design of antitumour therapies. We have sequenced the gene encoding the transmembrane protein tyrosine kinase ERBB2 (also known as HER2 or Neu) from 120 primary lung tumours and identified 4% that have mutations within the kinase domain; in the adenocarcinoma subtype of lung cancer, 10% of cases had mutations. ERBB2 inhibitors, which have so far proved to be ineffective in treating lung cancer, should now be clinically re-evaluated in the specific subset of patients with lung cancer whose tumours carry ERBB2 mutations.

The successful treatment of chronic myelogenous leukaemia with a drug (known as imatinib, marketed as Gleevec) that inhibits a mutant protein kinase has fostered interest in the development of other kinase inhibitors<sup>1</sup>. Gefitinib, an inhibitor of the epidermal growth-factor receptor (EGFR), induces a marked response in a small subset of lung cancers; activating mutations have been found in the EGFR gene in tumours that respond to gefitinib but are rare in those that do not respond<sup>2,3</sup>. The response to gefitinib as a treatment for lung cancer therefore seems to be predicated upon the presence of an EGFR mutation in the tumour.